

**COURTESY COPY OF THE  
PCT APPLICATION AS  
ORIGINALLY FILED  
WITH SEQUENCE LISTING  
AND ABSTRACT**

## TREATMENT OF T CELL MEDIATED DISEASES BY INHIBITION OF FGFR3

### FIELD OF THE INVENTION

The present invention relates to a method of preventing and treating T cell mediated  
5 diseases, including inflammatory autoimmune diseases and in particular rheumatoid  
arthritis, by administering to an individual in need thereof at least one inhibitor of fibroblast  
growth factor receptor 3 (FGFR3).

### BACKGROUND OF THE INVENTION

#### 10 T Cell Mediated Disease

The human immune system is a highly regulated cellular network that normally  
functions to defend the body from infection. In some instances, the immune system  
malfunctions and reacts to a host component as if it were foreign. Such a response results in  
an autoimmune disease, in which the host's immune system mistakenly attacks self,  
15 targeting the host's own tissue. T cells, the primary regulators of the immune system,  
directly or indirectly effect the autoimmune response. T cell-mediated diseases refer to any  
disease directly mediated by T cells and those indirectly mediated whereby a T cell  
response contributes to the production of abnormal antibodies and frequently an  
inflammatory response.

20 Aberrant immune mechanisms are believed to result in more than eighty diseases,  
among these are rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple  
sclerosis (MS), type I diabetes (juvenile onset, insulin mediated diabetes mellitus, IDDM),  
myasthenia gravis (MG) and psoriasis. Autoimmune diseases affect millions of people  
worldwide. In addition to the individual suffering generated by these diseases, the cost in  
25 terms of actual treatment expenditures and lost productivity is measured in billions of  
dollars annually.

#### Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease that  
primarily affects the small diarthrodial joints of the hands and feet. The disease manifests  
30 itself as inflammation of the normally acellular synovium, the joint lining, due to the  
infiltration of macrophages, T cells and other immune cells into the region. T cells appear  
to play an important role in the etiopathogenesis of RA since T-cell cytokines such as  
interleukin-2 (IL-2) and interferon- $\gamma$  are present in the synovium and synovial fluid.

Damage to the joints depends on three primary elements: inflammation, infiltration of the synovial tissue with immune cells and angiogenesis. The locally expressed degradative enzymes and cytokines digest the extracellular matrix and destroy the articular tissue resulting in chronic pain and irreversible damage of tendons, ligaments, joints, and bones.

5 RA affects approximately 0.5-1% of the adult population in the western world.

#### Biological Therapy for T Cell Mediated Disease

Novel biological approaches for treating autoimmune disease, including monoclonal antibodies, soluble receptors, and enzyme inhibitors, target pro-inflammatory cytokines, their cell surface receptors and cell types, have emerged as a result of the recent advances in  
10 understanding the physiopathology underlying inflammation. (reviewed in Smolen and Steiner, 2003; Nepom, 2002; Simón, 2001).

US 5,919,452 teaches the treatment of tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) mediated pathologies such as autoimmune and inflammatory autoimmune diseases by administering compounds such as anti-TNF $\alpha$  antibodies and anti-TNF $\alpha$  peptides. US 5,512,544 discloses  
15 the treatment of autoimmune disease comprising administering TNF $\alpha$  binding proteins, which are in effect soluble forms of the TNF receptor, to an individual in need thereof. US 6,333,032 discloses a method of treating an autoimmune disease in a human patient comprising administering an antibody to  $\gamma$ -interferon.

US 6,730,666, by some of the inventors of the present invention, teaches a method of  
20 inhibiting growth factor receptor tyrosine kinase activity in an individual in need thereof by administering a composition comprising a porphyrin or a derivative thereof. According to one embodiment of that invention, the compositions may be useful for the treatment rheumatoid arthritis and other autoimmune diseases, specifically by inhibiting VEGF (vascular endothelial growth factor) and NGF (nerve growth factor).

25 PCT application WO 01/57056 discloses a method for treating RA in an individual, comprising the step of expressing within the individual at least an immunologically recognizable portion of a cytokine from an exogenous polynucleotide wherein a level of expression of the at least a portion of the cytokine is sufficient to induce the formation of anti-cytokine immunoglobulins which serve to neutralize or ameliorate the activity of a  
30 respective endogenous cytokine. Expression of a molecule for inhibiting FGFR was neither taught nor suggested.

The use of anti-angiogenic compounds, specifically those which inhibit VEGF signaling, for the treatment of RA has been proposed (reviewed in Paleolog, 2002) based on the rationale that disruption of new blood vessel formation would prevent delivery of nutrients to the inflammatory site and may lead to vessel regression.

## 5 Fibroblast Growth Factors

Fibroblast Growth Factors (FGFs) constitute a family of over twenty structurally related polypeptides that are developmentally regulated and expressed in a wide variety of tissues. FGFs stimulate proliferation, cell migration and differentiation and play a major role in skeletal and limb development, wound healing, tissue repair, hematopoiesis,  
10 angiogenesis, and tumorigenesis (reviewed in Ornitz and Itoh, 2001).

The biological action of FGFs is mediated by specific cell surface receptors belonging to the receptor protein tyrosine kinase (RPTK) family of protein kinases. These proteins consist of an extracellular ligand binding domain, a single transmembrane domain and an intracellular tyrosine kinase domain that undergoes phosphorylation upon binding of FGF.  
15 The FGF receptor (FGFR) extracellular region contains three immunoglobulin-like (Ig-like) loops or domains (D1, D2 and D3), an acidic box, and a heparin-binding domain. Four FGFR genes encoding for multiple receptor variants have been identified to date.

A role for the FGF system and receptors in T cell mediated disease has yet to be defined. An increase in endogenous production of FGF2 in the synovial fluid of RA  
20 patients may contribute to joint destruction by inducing osteoclastogenesis (Manabe, et al., 1999). A neutralizing anti-FGF2 antibody was shown to inhibit osteoclastogenesis induced by RA synovial fluid in a cell culture system (Manabe, et al., 1999) and to attenuate the clinical symptoms and histopathological abnormalities in a rat adjuvant induced arthritis (AIA) model (Yamashita, et al., 2002). Japanese patent publication 2002-229883 discloses  
25 a bFGF (FGF2) antagonist as a therapeutic agent for treating chronic rheumatoid arthritis.

PCT publication WO 02/102973, co-assigned to the assignee of the present invention, discloses antibodies to receptor tyrosine kinases, specifically anti-Fibroblast Growth Factor Receptor 3 (FGFR3) antibodies. Certain antibodies shown to be specific for FGFR3 are useful to neutralize FGFR3 activity and for the treatment of skeletal dysplasias such as  
30 achondroplasia and proliferative diseases such as bladder cancer and multiple myeloma.

International patent application WO 03/023004 discloses antisense modulation of FGFR3 expression for the treatment of skeletal and proliferative disorders. T cell mediated diseases are neither taught nor suggested.

The art neither teaches nor suggests the use of FGFR3 inhibitors, including anti-FGFR3  
5 antibodies, for the prevention or treatment of T cell mediated autoimmune inflammatory diseases.

Citation of any document herein is not intended as an admission that such document is pertinent prior art, or considered material to the patentability of any claim of the present application.

10

### SUMMARY OF THE INVENTION

It is now disclosed that the inhibition of fibroblast growth factor receptor 3 (FGFR3) activity represents for the first time a novel and unexpected means of treating T cell mediated inflammatory or autoimmune diseases. The present invention relates to the  
15 prevention, attenuation or treatment of an autoimmune disease by administering a therapeutically effective amount of at least one FGFR3 inhibitor to a mammal in need thereof. The methods of the present invention are effective in treatment of T-cell mediated inflammatory or autoimmune diseases including but not limited to rheumatoid arthritis (RA), collagen II arthritis, multiple sclerosis (MS), systemic lupus erythematosus (SLE),  
20 psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, sarcoidosis, autoimmune uveitis, inflammatory bowel disease (Crohn's and ulcerative colitis), celiac disease and myasthenia gravis.

In one aspect the present invention is related to a method of preventing, attenuating or treating the symptoms of a T-cell mediated inflammatory or autoimmune disease  
25 comprising administering a pharmaceutical composition comprising a therapeutically effective amount of at least one FGFR3 inhibitor and a pharmaceutically acceptable carrier. Another aspect relates to the use of at least one FGFR3 inhibitor for the manufacture of a medicament for the treatment of a T cell mediated inflammatory autoimmune disease.

An inhibitor may be selected from diverse types of compounds. According to certain  
30 embodiments a FGFR3 inhibitor is a molecule comprising at least the antigen-binding portion of an antibody having a specific affinity for fibroblast growth factor receptor 3 (FGFR3). According to other embodiments a FGFR3 specific inhibitor useful in treating a

T cell mediated inflammatory or autoimmune disease is selected from a FGFR3 specific small organic molecule tyrosine kinase inhibitor, a FGFR3 specific soluble receptor, a FGFR3 peptide or peptidomimetic, a FGFR3 specific RNA inhibitor, a FGFR3 specific antagonist ligand or a DNA vaccine encoding FGFR3 or a fragment thereof, an FGFR3  
5 specific inhibitor of heparan sulfate binding.

In one embodiment, the present invention provides a method of treating a T cell mediated inflammatory autoimmune disease by administering a pharmaceutical composition comprising at least one therapeutically effective FGFR3 inhibitor selected from the group consisting of a molecule comprising at least the antigen-binding portion of  
10 an antibody having a specific affinity for fibroblast growth factor receptor 3 (FGFR3), a FGFR3 specific small organic molecule tyrosine kinase inhibitor, a FGFR3 specific soluble receptor, a FGFR3 specific peptide or peptidomimetic, a FGFR3 specific RNA inhibitor, a FGFR3 specific antagonist ligand and a DNA vaccine encoding FGFR3 or a fragment thereof, an FGFR3 specific inhibitor of heparin binding.

15 In another embodiment, the present invention provides the use of a FGFR3 inhibitor selected from the group consisting of a molecule comprising the antigen-binding portion of an antibody which has a specific affinity for fibroblast growth factor receptor 3 (FGFR3), a FGFR3 specific small organic molecule tyrosine kinase inhibitor, a FGFR3 specific soluble receptor, a FGFR3 specific peptide or peptidomimetic, a FGFR3 specific RNA inhibitor, a  
20 FGFR3 specific antagonist ligand and a DNA vaccine encoding FGFR3 or a fragment thereof, an FGFR3 specific inhibitor of heparin binding, for the manufacture of a medicament for the prevention and treatment of a T cell mediated inflammatory autoimmune disease.

According to certain embodiments of the present invention the FGFR3 inhibitor is a  
25 molecule that comprises the antigen-binding portion of an antibody which has a specific affinity for fibroblast growth factor receptor 3 (FGFR3). In a preferred embodiment the molecule comprises the antigen-binding portion of an antibody which has specific affinity for the extracellular domain of fibroblast growth factor receptor 3 (FGFR3).

According to certain embodiments the antibody is polyclonal, monoclonal, or  
30 proteolytic fragments thereof such as the Fab or F(ab')<sub>2</sub> fragments. Additional embodiments include chimeric antibodies; human and humanized antibodies; recombinant and engineered antibodies, and fragments thereof. A preferred antibody species is a single chain antibody.

Single chain antibodies can be single chain composite polypeptides having antigen binding capabilities and comprising amino acid sequences homologous or analogous to the variable regions of an immunoglobulin light and heavy chain i.e. linked  $V_H$ - $V_L$  or single chain Fv (scFv).

5        Some of the molecules and compositions thereof described herein have been disclosed in PCT patent application WO 02/102972, the teachings of which are incorporated by reference as if fully set forth herein, co-assigned to the assignee of the present invention. These compositions were disclosed previously as being useful for treating skeletal dysplasias and proliferative diseases.

10        It is now disclosed that said known compositions are unexpectedly useful for the treatment of a T cell mediated inflammatory or autoimmune disease including but not limited to rheumatoid arthritis, collagen II arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, sarcoidosis, celiac disease, autoimmune uveitis, inflammatory bowel disease (Crohn's and  
15 ulcerative colitis) and myasthenia gravis.

In certain embodiments the present invention provides a method of treating or preventing a T cell mediated inflammatory or autoimmune disease comprising administering a composition comprising a therapeutically effective molecule comprising a  $V_H$ -CDR3 region having a polypeptide sequence as set forth in anyone of SEQ ID NOS: 1-  
20 9 and a  $V_L$ -CDR3 region having a polypeptide sequence as set forth in anyone of SEQ ID NOS: 10-18, and a pharmaceutically acceptable carrier. The corresponding polynucleotide sequences of the  $V_H$ -CDR3 and  $V_L$ -CDR3 regions are set forth in SEQ ID NOS: 39-47 and SEQ ID NOS: 48-56, respectively. These sequences were disclosed previously in WO 02/102972, assigned to some of the applicants of the present invention.

25        According to various additional embodiments the present invention provides a method of treating or preventing a T cell mediated inflammatory or autoimmune disease comprising administering a composition comprising a therapeutically effective molecule comprising a  $V_H$  domain having a polypeptide sequence as set forth in anyone of SEQ ID NOS: 19-27 and the  $V_L$  domains having a polypeptide sequence as set forth in anyone of SEQ ID NOS:  
30 28-36, and a pharmaceutically acceptable carrier. The corresponding polynucleotide sequences of the  $V_H$  and  $V_L$  domains are set forth in SEQ ID NOS: 57-65 and SEQ ID NOS: 66-74, respectively.

In a preferred embodiment, the present invention provides a method of treating or preventing a T cell mediated inflammatory or autoimmune disease comprising administering a pharmaceutical composition which comprises a molecule comprising a V<sub>H</sub>-CDR3 region and a V<sub>L</sub>-CDR3 region set forth in SEQ ID NO:1 and SEQ ID NO:10, 5 respectively, and a pharmaceutically acceptable carrier. In another preferred embodiment the pharmaceutical composition comprises a V<sub>H</sub> domain and a V<sub>L</sub> domain set forth in SEQ ID NO: 19 and SEQ ID NO:27, respectively, and a pharmaceutically acceptable carrier. In yet another preferred embodiment the pharmaceutical composition comprises a single chain Fv molecule (scFv) set forth in SEQ ID NO:37, having corresponding polynucleotide 10 sequence SEQ ID NO:38, and a pharmaceutically acceptable carrier.

In another embodiment, the present invention provides a method of treating a T cell mediated inflammatory or autoimmune disease by administering a composition comprising at least one FGFR3 inhibitor wherein the inhibitor is a FGFR3 specific small organic molecule tyrosine kinase inhibitor, and a pharmaceutically acceptable carrier. According to 15 certain embodiments of the present invention a small molecule tyrosine kinase (TK) inhibitor having FGFR3 specificity is useful for preventing, attenuating or treating a T cell mediated inflammatory autoimmune disease.

In yet another embodiment, the present invention provides a method of treating a T cell mediated inflammatory autoimmune disease by administering a pharmaceutical 20 composition comprising at least one FGFR3 inhibitor wherein the inhibitor is a FGFR3 specific soluble receptor, and a pharmaceutically acceptable carrier. In a non-limiting example, a secreted receptor, also known as a soluble receptor, comprises the extracellular ligand-binding portion of the FGFR3 receptor, per se or fused to the constant region (Fc) of a human immunoglobulin (Ig) chain.

25 In yet another embodiment, the present invention provides a method of treating a T cell mediated inflammatory or autoimmune disease by administering a pharmaceutical composition comprising at least one FGFR3 inhibitor wherein the inhibitor is a FGFR3 specific peptide inhibitor, and a pharmaceutically acceptable carrier. A peptide inhibitor includes FGFR3 specific peptides, peptide analogs having amino acid sequence derived 30 from the extracellular portion of the fibroblast growth factor receptor 3 (FGFR3) and peptidomimetics based on the structure of such peptides.



In yet another embodiment, the present invention provides a method of treating a T cell mediated inflammatory or autoimmune disease by administering a pharmaceutical composition comprising at least one FGFR3 inhibitor wherein the inhibitor is a FGFR3 specific antagonist ligand, and a pharmaceutically acceptable carrier. Non-limiting  
5 examples of ligands antagonistic to FGFR3 may be found in copending PCT publication WO 03/094835, assigned to the assignee of the present invention.

In yet another embodiment, the present invention provides a method of treating a T cell mediated inflammatory or autoimmune disease by administering a pharmaceutical composition comprising at least one FGFR3 inhibitor wherein the inhibitor is a FGFR3  
10 specific RNA inhibitor, and a pharmaceutically acceptable carrier. RNA inhibition (RNAi) is based on antisense modulation of FGFR3 in cells and tissues comprising contacting the cells and tissues with at least one antisense molecule, including but not limited to double stranded RNA, (dsRNA), small interfering RNA (siRNA), ribozymes and locked nucleic acids (LNAs), and a pharmaceutically acceptable carrier. In certain specific embodiments  
15 the RNA inhibiting molecule is an antisense oligonucleotide or an oligonucleotide mimetic comprising from about 8 to about 50 nucleotides.

In another embodiment, the present invention provides a method of treating a T cell mediated inflammatory or autoimmune disease by administering a pharmaceutical composition comprising at least one FGFR3 inhibitor wherein the inhibitor is a DNA  
20 vaccine encoding FGFR3 or a fragment thereof, and a pharmaceutically acceptable carrier. DNA vaccination provides an effective means of long term antigen expression *in vivo* for the generation of both humoral and cellular immune responses. According to various embodiments of the present invention the DNA vaccines encode active fragments of FGFR3. The preferred fragments are polynucleotides encoding the extracellular domain of  
25 FGFR3, in particular amino acids about 1-370 or fragments thereof. The FGFR3 according to the present invention is preferably human, however other mammalian FGFR3 proteins are within the scope of the invention.

## BRIEF DESCRIPTION OF THE FIGURES

30 Figure 1 shows the effect of certain FGFR3 inhibitors on limb swelling in a murine Collagen Induced Arthritis (CIA) model.

Figure 2 depicts the effect of certain FGFR3 inhibitors in a delayed type hypersensitivity assay in a murine model.

Figure 3 shows the interferon gamma secretion of lymphocytes isolated from FGFR3 inhibitor treated and non-treated animals.

## 5 DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the discovery that inhibition or attenuation of fibroblast growth factor receptor 3 (FGFR3)-mediated signaling results in the prevention and treatment of T cell mediated inflammatory or autoimmune diseases including, but not limited to, rheumatoid arthritis. It is now disclosed that the inhibition of fibroblast growth factor receptor 3 (FGFR3) represents a novel and unexpected means of treating a T cell mediated inflammatory or autoimmune disease. The present invention relates to the prevention, attenuation or treatment of autoimmune disease by administering a therapeutically effective amount of at least one FGFR3 inhibitor to a mammal in need thereof. The methods of the present invention are effective in treatment of T-cell mediated inflammatory or autoimmune disease including, but not limited to, rheumatoid arthritis, collagen II arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, sarcoidosis, celiac disease, autoimmune uveitis, inflammatory bowel disease (Crohn's and ulcerative colitis) and myasthenia gravis.

The present invention further relates to the use of at least one FGFR3 inhibitor for the manufacture of a medicament for the prevention, attenuation or treatment of a T cell mediated inflammatory or autoimmune disease, including but not limited to rheumatoid arthritis.

FGFR3 inhibitors may be selected from diverse types of compounds and molecules and may inhibit FGFR3 signaling by a variety of means. Without wishing to be bound to any particular theory, a FGFR3 inhibitor may inhibit FGFR3 activity by transcriptional, post-transcriptional, translational or post translational mechanisms known to inhibit receptor tyrosine kinase activity. The inhibitor may inhibit FGFR3 activity by interfering at the extracellular or intracellular level and may inhibit any known FGFR3 isoform.

In a non-limiting example, a FGFR3 inhibitor may be an antigen binding molecule of different types such as polyclonal or monoclonal antibodies or a monoclonal antibody fragment. It may take the form of a FGFR3 soluble receptor per se or the form of a soluble receptor fusion protein, for example a fusion protein using a Fc fragment. A FGFR3

inhibitor may be a FGFR3 specific small organic molecule tyrosine kinase inhibitor, a FGFR3 specific peptide or peptidomimetic, a FGFR3 specific RNA inhibitor, FGFR3 specific ligand antagonist and a DNA vaccine encoding FGFR3 or a fragment thereof.

PCT publication WO 02/102972, co-assigned to the assignee of the present invention, 5 discloses monoclonal antibodies to receptor protein tyrosine kinases, including specific anti-Fibroblast Growth Factor Receptor 3 (FGFR3) antibodies. Certain antibodies were shown to be specific for FGFR3 and useful to neutralize FGFR3 activity and for the treatment of skeletal dysplasias such as achondroplasia and proliferative diseases such as bladder cancer and multiple myeloma. Utilizing a soluble dimeric form of the extracellular 10 domain of the FGFR3 receptor to screen for antibodies (e.g., Fabs) from a phage display antibody library yielded numerous high affinity ( $K_D < 50$  nM) antibodies (Fabs) that bind FGFR3 and interfere with ligand binding, thereby blocking ligand-dependent activation of FGFR3. Additional antibodies useful for blocking ligand-independent, or constitutive, activation were also identified and isolated.

15 The present inventors have now discovered that certain molecules disclosed in that application are useful for the prevention and treatment of T cell mediated inflammatory or autoimmune diseases, including but not limited to rheumatoid arthritis, collagen II arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, sarcoidosis, autoimmune uveitis, inflammatory bowel 20 disease (Crohn's and ulcerative colitis), celiac disease and myasthenia gravis.

For convenience certain terms employed in the specification, examples and claims are described herein.

The term "fibroblast growth factor receptor" or "FGFR" denotes a receptor specific for FGF which is necessary for transducing the signal exerted by FGF to the cell interior, 25 typically comprising an extracellular ligand-binding domain, a single transmembrane helix, and a cytoplasmic domain having tyrosine kinase activity. The FGFR extracellular domain consists of three immunoglobulin-like (Ig-like) domains (D1, D2 and D3), a heparin binding domain and an acidic box. Four FGFR genes that encode for multiple receptor protein variants are known. Alternative splicing of the FGFR3 mRNAs generates at least 30 two known isoforms of the receptors, FGFR3IIIc and FGFR3IIb.

Throughout the specification and the claims that follow, the term "FGFR3 specific" refers to any effector that has higher affinity or activity or binding to FGFR3 polypeptide or to the polynucleotide encoding same, than to another FGF receptor protein or polynucleotide. The effector can be any molecule including a ligand, an inhibitor, an antibody, a polypeptide, a polynucleotide or a small organic molecule such as a tyrosine kinase inhibitor. It is to be explicitly understood that the term "FGFR3 specific" does not exclude or preclude situations wherein the effector has some activity on another FGF receptor subtype. It is further to be understood that if the activity mediated via another receptor subtype is clinically important for the therapeutic utility observed, this is explicitly encompassed within the scope of the claimed invention.

As used herein "T cell mediated inflammatory or autoimmune diseases" are diseases directly or indirectly effected by the T cells of the immune system. Non-limitative examples include rheumatoid arthritis, collagen II arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, sarcoidosis, autoimmune uveitis, inflammatory bowel disease (Crohn's and ulcerative colitis), celiac disease and myasthenia gravis.

One aspect of the present invention is directed to a method of preventing, attenuating or treating a T cell mediated inflammatory or autoimmune disease by administering a molecule comprising the antigen-binding portion of an antibody which diminishes or inhibits activation of FGFR3, and a pharmaceutically acceptable carrier. According to one embodiment of the present invention the antigen-binding portion of an antibody is directed to the extracellular domain of the FGFR3.

One embodiment of the present invention is directed to molecules comprising an antigen binding domain which blocks ligand-dependent activation of FGFR3.

The molecule having the antigen-binding portion of an antibody according to the present invention is useful for blocking the ligand-dependent activation and/or ligand independent (constitutive) activation of FGFR3. Preferred embodiments of such antibodies/molecules, obtained from an antibody library designated as HuCAL<sup>®</sup> (Human Combinatorial Antibody Library) clone, are presented in Table 1 with the unique V<sub>H</sub>-CDR3 and V<sub>L</sub>-CDR3 sequences presented in Table 2.

Table 1: Properties of antibodies useful for inhibiting, treating or attenuating  
T cell mediated inflammatory or autoimmune diseases.

Clone	Affinity to FGFR3 (BIAcore) nM	Affinity to FGFR3 (FACS) nM	Affinity to FGFR1 nM	K <sub>off</sub> (s <sup>-1</sup> )	IC <sub>50</sub> FGFR3 (FGF9) nM	Domain Specificity
PRO-001	1.5	0.7	-	7.1x10e-4	19	2
PRO-002	37	43	-	2x10e-2	360	2
PRO-012	14	6.5	-	2.3x10e-3	58	2
PRO-021	9	1.1	-	3.6x10e-3	50	3c
PRO-024	10	NA	-	5.4x10e-3	70	3c
PRO-026	4	1.4	32	5 x 10e-4	70	3c
PRO-029	6	<1	29	1.4x10e-3	20	3c
PRO-054	3.7	NA	2.5	2x10e-3	45	3c
PRO-055	2.9	NA	-	7.4x10e-4	34	3c

Key: affinity (nM) of the respective molecules to FGFR3 and FGFR1 was measured by BIAcore and/or FACS. IC<sub>50</sub> were determined for the dimeric dHLX format of certain molecule with antigen binding site in an FDCEP-FGFR3 proliferation assay performed with FGF9. Fab-dHLX refers to a Fab mini-antibody format where a dimer of the Fab monomer is produced as a fusion protein after insertion into an expression vector.

Table 2: V<sub>H</sub>-CDR3 and corresponding V<sub>L</sub>-CDR3 polypeptide sequences

Clone	V <sub>H</sub> -CDR3	V <sub>L</sub> -CDR3
PRO-001	SYYPDFDY (SEQ ID NO:1)	QSYDGPDLW (SEQ ID NO:10)
PRO-002	DFLGYEFDY (SEQ ID NO:2)	QSYDYSADY (SEQ ID NO:11)
PRO-012	YHSWYEMGYG GSTVGYMFDY (SEQ ID NO:3)	QSYDFDFA (SEQ ID NO:12)
PRO-021	DNWFKPFSDV (SEQ ID NO:4)	QQYDSIPY (SEQ ID NO:13)
PRO-024	VNHWTYTFDY (SEQ ID NO:5)	QQMSNYPD (SEQ ID NO:14)
PRO-026	GYWYAYFTYI NYGYFDN (SEQ ID NO:6)	QSYDNNSDV (SEQ ID NO:15)
PRO-029	TWQYSYFYLL DGGYYFDI (SEQ ID NO:7)	QQTNNAAPV (SEQ ID NO:16)
PRO-054	NMAYTNYQYV NMPHFDY (SEQ ID NO:8)	QSYDYFKL (SEQ ID NO:17)
PRO-055	SMNSTMYWYL RRVLFDDH (SEQ ID NO:9)	QSYDMYMYI (SEQ ID NO:18)

V<sub>H</sub> refers to the variable heavy chain, V<sub>L</sub> refers to the variable light chain, CDR3 refers to complementarity determining region 3. In certain preferred embodiments the present invention provides a method of treating or preventing T cell mediated inflammatory or autoimmune disease comprising administering a composition comprising a therapeutically effective molecule comprising a V<sub>H</sub>-CDR3 region having a polypeptide sequence as set forth in any one of SEQ ID NOS: 1-9 and a corresponding V<sub>L</sub>-CDR3 region having a polypeptide sequence as set forth in any one of SEQ ID NOS:10-18, and a pharmaceutically acceptable carrier. The corresponding polynucleotide sequences of the V<sub>H</sub>-CDR3 and V<sub>L</sub>-CDR3 regions as set forth in any one of SEQ ID NOS: 39-47 and SEQ ID NOS: 48-56, respectively. The polynucleotide sequences are presented in Table 3.

According to certain embodiments the present invention provides a method of treating or preventing T cell mediated inflammatory or autoimmune disease comprising administering a composition comprising a therapeutically effective molecule comprising a V<sub>H</sub> domain having a polypeptide sequence as set forth in any one of SEQ ID NOS: 19-27 and the corresponding V<sub>L</sub> domains having a polypeptide sequence as set forth in any one of SEQ ID NOS: 28-36, and a pharmaceutically acceptable carrier. The preferred V<sub>H</sub> and V<sub>L</sub> sequences are presented herein.

## PRO-001-VH (SEQ ID NO:19)

1	QVQLQQSGPG	LVKPSQTL	SL	TCAISGDSVS	SNSAAWNWIR	QSPGRGLEWL
51	GRTYYRSKWY	NDYAVSVKSR	ITINPDTSKN	QFSLQLNSVT	PEDTAVYYCA	
101	RSYYPDFDYW	GQGLTVTVSS				

## PRO-002-VH (SEQ ID NO:20)

1	QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	SYMHVVRQA	PGQGLEWMGW
51	INPNSGGTNY	AQKFQGRVTM	TRDTSISTAY	MELSSLRSED	TAVYYCARDF
101	LGYEFDYWGQ	GTLTVTVSS			

## PRO-012-VH (SEQ ID NO:21)

1	QVQLKESGPA	LVKPTQTLTL	TCTFSGFSL	TSGVGVGWIR	QPPGKALEWL
51	ALIDWDDDKY	YSTSLKTRLT	ISKDTSKNQV	VLTMTNMDPV	DTATYYCARY
101	HSWYEMGYG	STVGVMFDYW	GQGLTVTVSS		

## PRO-021-VH (SEQ ID NO:22)

1	QVQLVQSGAE	VKKPGSSVKV	SCKASGGTFS	SYAISWVRQA	PGQGLEWMGG
51	IIPIFGTANY	AQKFQGRVTI	TADESTSTAY	MELSSLRSED	TAVYYCARDN
101	WFKPFSDVWG	QGLTVTVSS			

## PRO-024-VH (SEQ ID NO:23)

1	QVQLVQSGAE	VKKPGSSVKV	SCKASGGTFS	SYAISWVRQA	PGQGLEWMGG
51	IIPIFGTANY	AQKFQGRVTI	TADESTSTAY	MELSSLRSED	TAVYYCARVN
101	HWTYTFDYWG	QGLTVTVSS			

MS-Pro-26-VH (SEQ ID NO:24)

1 QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWVRQA PGQGLEWMGW  
 51 INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSSLRSED TAVYYCARGY  
 101 WYAYFTYINY GYFDNWGQGT LTVVSS

5

PRO-029-VH (SEQ ID NO:25)

1 QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWVRQA PGQGLEWMGW  
 51 INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSSLRSED TAVYYCARTW  
 101 QYSYFYYLDG GYFDDIWGQG TLTVVSS

10

PRO-054-VH (SEQ ID NO:26)

1 QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWVRQA PGQGLEWMGW  
 51 INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSSLRSED TAVYYCARNM  
 101 AYTNYQYVNM PHFDYWGQGT LTVVSS

15

PRO-055-VH (SEQ ID NO:27)

1 QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWVRQA PGQGLEWMGW  
 51 INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSSLRSED TAVYYCARS  
 101 NSTMYWYLRR VLFDHWGQGT LTVVSS

20

PRO-001-VL (SEQ ID NO:28)

1 DIELTQPPSV SVAPGQTARI SCSGDALGDK YASWYQQKPG QAPVLVIYDD  
 51 SDRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQSY DGPDLWVFGG  
 101 GTKLTVLGQ

25

PRO-002-VL (SEQ ID NO:29)

1 DIELTQPPSV SVAPGQTARI SCSGDALGDK YASWYQQKPG QAPVLVIYDD  
 51 SDRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQSY DYSADYVFGG  
 101 GTKLTVLGQ

30

PRO-012-VL (SEQ ID NO:30)

1 DIELTQPPSV SVAPGQTARI SCSGDALGDK YASWYQQKPG QAPVLVIYDD  
 51 SDRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQSY DFDFAVFGGG  
 101 TKLTVLGQ

35

PRO-021-VL (SEQ ID NO:31)

1 DIVMTQSPDS LAVSLGERAT INCRSSQSVL YSSNNKNYLA WYQQKPGQPP  
 51 KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQQYDSI  
 101 PYTFGQGTKV EIKRT

40

PRO-024-VL (SEQ ID NO:32)

1 DIVLTQSPAT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY  
 51 GASSRATGVP ARFSGSGSGT DFTLTISSE PEDFATYYCQ QMSNYPDTFG  
 101 QGTKVEIKRT

45

MS-Pro-26-VL (SEQ ID NO:33)

1 DIALTQPASV SGSPGQSITI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLM  
 51 YDVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC QSYDNNSDVV  
 101 FGGGTKLTVL GQ

50

PRO-029-VL (SEQ ID NO:34)

1 DIVLTQSPAT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY  
 51 GASSRATGVP ARFSGSGSGT DFTLTISSE PEDFATYYCQ QTNNAPVTFG  
 101 QGTKVEIKRT

PRO-054-VL (SEQ ID NO:35)

1 DIELTQPPSV SVAPGQTARI SCSGDALGDK YASWYQQKPG QAPVLVIYDD  
5 51 SDRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQSY DYFKLVFGGG  
10 101 TKLTVLGQ

PRO-055-VL (SEQ ID NO:36)

1 DIALTQPASV SGSPGQSITI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLM I  
10 51 YDVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC QSYDMYNYIV  
101 FGGGTKLTVL GQ

The corresponding polynucleotide sequences of the V<sub>H</sub> and V<sub>L</sub> domains have SEQ ID NOS: 57-65 and SEQ ID NOS: 66-74, respectively.

<SEQ ID NO:57;DNA> PRO-001 VH

15 CAGGTGCAATTGCAACAGTCTGGTCCGGGCTGGTGAAACCGAGCCAAACCCTGAGCCTGACCTGTG  
CGATTTCCGGAGATAGCGTGAGCAGCAACAGCGCGGCGTGGAACCTGGATTTCGCCAGTCTCCTGGGCG  
TGGCCTCGAGTGGCTGGGCCGTACCTATTATCGTAGCAAATGGTATAACGATTATGCGGTGAGCGTG  
AAAAGCCGGATTACCATCAACCCGGATACTTCGAAAAACAGTTTAGCCTGCAACTGAACAGCGTGA  
CCCCGGAAGATACGGCCGTGTATTATTGCGCGCGTTCTTATTATCCTGATTTTGATTATTGGGGCCA  
20 AGGCACCCTGGTGACGGTTAGCTCAGC

<SEQ ID NO:58;DNA> PRO-002 VH

15 CAGGTGCAATTGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGCGAGCGTGAAAGTGAGCTGCA  
AAGCCTCCGGATATACCTTTACCAGCTATTATATGCACTGGGTCCGCCAAGCCCCTGGGCAGGGTCT  
CGAGTGGATGGGCTGGATTAACCCGAATAGCGGCGGCACGAACTACGCGCAGAAGTTTCAGGGCCG  
25 GGTGACCATGACCCGTGATACAGCATTAGCACC GCGTATATGGAACCTGAGCAGCCTGCGTAGCGAA  
GATACGGCCGTGTATTATTGCGCGCGTGATTTTCTTGGTTATGAGTTTGATTATTGGGGCCAAGGCA  
CCCTGGTGACGGTTAGCTCAGC

<SEQ ID NO:59;DNA> PRO-012 VH

30 CAGGTGCAATTGAAAGAAAGCGGCCCGGCCCTGGTGAAACCGACCCAAACCCTGACCCTGACCTGTA  
CCTTTTCCGGATTTAGCCTGTCCACGTCTGGCGTTGGCGTGGGCTGGATTTCGCCAGCCGCTGGGAA  
AGCCCTCGAGTGGCTGGCTCTGATTGATTGGGATGATGATAAGTATTATAGCACCAGCCTGAAAC  
GCGTCTGACCATTAGCAAAGATACTTCGAAAAATCAGGTGGTGCTGACTATGACCAACATGGACCCG  
GTGGATACGGCCACCTATTATTGCGCGCGTTATCATTTCTTGGTATGAGATGGGTTATTATGGTTCTA  
35 CTGTTGGTTATATGTTTGATTATTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCAGC

<SEQ ID NO:60;DNA> PRO-021 VH

40 CAGGTGCAATTGGTTCAGTCTGGCGCGGAAGTGAAAAAACCGGGCAGCAGCGTGAAAGTGAGCTGCA  
AAGCCTCCGGAGGCACTTTTAGCAGCTATGCGATTAGCTGGGTGCGCCAAGCCCCTGGGCAGGGTCT  
CGAGTGGATGGGCGGCATTATTCCGATTTTTTGGCACGGCGAACTACGCGCAGAAGTTTCAGGGCCGG  
GTGACCATTACCGCGGATGAAAGCACCAGCACC GCGTATATGGAACCTGAGCAGCCTGCGTAGCGAAG  
ATACGGCCGTGTATTATTGCGCGCGTGATAATTGGTTTAAGCCTTTTTCTGATGTTTGGGGCCAAGG  
CACCTGGTGACGGTTAGCTCAGC

45 <SEQ ID NO:61;DNA> PRO-024 VH

CGTGAAAGTGAGCTGCAAAGCCTCCGGAGGCACTTTTAGCAGCTATGCGATTAGCTGGGTGCGCCAA  
GCCCCTGGGCAGGGTCTCGAGTGGATGGGCGGCATTATTCCGATTTTTTGGCACGGCGAACTACGCGC  
AGAAGTTTCAGGGCCGGGTGACCATTAACCGCGGATGAAAGCACCAGCACC GCGTATATGGAACCTGAG  
CAGCCTGCGTAGCGAAGATACGGCCGTGTATTATTGCGCGCGTGTTAATCATTGGACTTATACTTTT  
50 GATTATTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCAGC



<SEQ ID NO:62;DNA> PRO-026 VH

CGTGAAAGTGAGCTGCAAAGCCTCCGGATATACCTTTACCAGCTATTATATGCACTGGGTCCGCCAA  
GCCCCTGGGCAGGGTCTCGAGTGGATGGGCTGGATTAACCCGAATAGCGGCGGCACGAACCTACGCGC  
AGAAGTTTCAGGGCCGGGTGACCATGACCCGTGATACCAGCATTAGCACCGCGTATATGGAAGTGA  
5 CAGCCTGCGTAGCGAAGATACGGCCGTGTATTATTGCGCGCGTGGTTATTGGTATGCTTATTTTACT  
TATATTAATTATGGTTATTTTGATAATTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCAGC

<SEQ ID NO:63;DNA> PRO-029 VH

CAGGTGCAATTGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGCGAGCGTGAAAGTGAGCTGCA  
10 AAGCCTCCGGATATACCTTTACCAGCTATTATATGCACTGGGTCCGCCAAGCCCCTGGGCAGGGTCT  
CGAGTGGATGGGCTGGATTAACCCGAATAGCGGCGGCACGAACCTACGCGCAGAAGTTTCAGGGCCGG  
GTGACCATGACCCGTGATACCAGCATTAGCACCGCGTATATGGAAGTGAAGCAGCCTGCGTAGCGAAG  
ATACGGCCGTGTATTATTGCGCGCGTACTTGGCAGTATTCTTATTTTATTATCTTGATGGTGGTTA  
15 TTATTTTGATATTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCAGC

<SEQ ID NO:64;DNA> PRO-054 VH

CAGGTGCAATTGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGCGAGCGTGAAAGTGAGCTGCA  
AAGCCTCCGGATATACCTTTACCAGCTATTATATGCACTGGGTCCGCCAAGCCCCTGGGCAGGGTCT  
20 CGAGTGGATGGGCTGGATTAACCCGAATAGCGGCGGCACGAACCTACGCGCAGAAGTTTCAGGGCCGG  
GTGACCATGACCCGTGATACCAGCATTAGCACCGCGTATATGGAAGTGAAGCAGCCTGCGTAGCGAAG  
ATACGGCCGTGTATTATTGCGCGCGTAATATGGCTTATACTAATTATCAGTATGTTAATATGCCTCA  
TTTTGATTATTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCAGC

<SEQ ID NO:65;DNA> PRO-055 VH

CAGGTGCAATTGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGCGAGCGTGAAAGTGAGCTGCA  
25 AAGCCTCCGGATATACCTTTACCAGCTATTATATGCACTGGGTCCGCCAAGCCCCTGGGCAGGGTCT  
CGAGTGGATGGGCTGGATTAACCCGAATAGCGGCGGCACGAACCTACGCGCAGAAGTTTCAGGGCCGG  
GTGACCATGACCCGTGATACCAGCATTAGCACCGCGTATATGGAAGTGAAGCAGCCTGCGTAGCGAAG  
ATACGGCCGTGTATTATTGCGCGCGTAAATATGGCTTATACTAATTATCAGTATGTTAATATGCCTCA  
30 TTTTGATCATTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCAGC

<SEQ ID NO:66> PRO-001 VL

GATATCGAACTGACCCAGCCGCTTCAGTGAGCGTTGCACCAGGTGAGACCGCGCGTATCTCGTGTA  
GCGGCGATGCGCTGGGCGATAAATACGCGAGCTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTTCT  
35 GGTGATTTATGATGATTCTGACCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAACAGCGGC  
AACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATTGCCAGAGCT  
ATGACGGTCCTGATCTTTGGGTGTTTGGCGGCGGCACGAAGTTAACCGTTCTTGGCCAG

<SEQ ID NO:67;DNA> PRO-002 VL

GATATCGAACTGACCCAGCCGCTTCAGTGAGCGTTGCACCAGGTGAGACCGCGCGTATCTCGTGTA  
40 GCGGCGATGCGCTGGGCGATAAATACGCGAGCTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTTCT  
GGTGATTTATGATGATTCTGACCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAACAGCGGC  
AACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATTGCCAGAGCT  
45 ATGACTATTCTGCTGATTATGTGTTTGGCGGCGGCACGAAGTTAACCGTTCTTGGCCAG

<SEQ ID NO:68;DNA> PRO-012 VL

GATATCGAACTGACCCAGCCGCTTCAGTGAGCGTTGCACCAGGTGAGACCGCGCGTATCTCGTGTA  
GCGGCGATGCGCTGGGCGATAAATACGCGAGCTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTTCT  
GGTGATTTATGATGATTCTGACCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAACAGCGGC  
50 AACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATTGCCAGAGCT  
ATGACTTTGATTTTGTGTGTTTGGCGGCGGCACGAAGTTAACCGTTCTTGGCCAG

<SEQ ID NO:69;DNA> PRO-021 VL

GATATCGTGATGACCCAGAGCCCGGATAGCCTGGCGGTGAGCCTGGGCGAACGTGCGACCATTAACT  
GCAGAAGCAGCCAGAGCGTGCTGTATAGCAGCAACAACAAAACTATCTGGCGTGGTACCAGCAGAA  
ACCAGGTCAGCCGCCGAACTATTAATTTATTGGGCATCCACCCGTGAAAGCGGGGTCCCGGATCGT  
5 TTTAGCGGCTCTGGATCCGGCACTGATTTTACCCTGACCATTTCGTCCCTGCAAGCTGAAGACGTGG  
CGGTGTATTATTGCCAGCAGTATGATTCTATTCCTTATACCTTTGGCCAGGGTACGAAAGTTGAAAT  
TAAACGTACG

<SEQ ID NO:70;DNA> PRO-024 VL

10 GATATCGTGCTGACCCAGAGCCCGGCGACCCTGAGCCTGTCTCCGGGCGAACGTGCGACCCTGAGCT  
GCAGAGCGAGCCAGAGCGTGAGCAGCAGCTATCTGGCGTGGTACCAGCAGAAACCAGGTCAAGCACC  
GCGTCTATTAATTTATGGCGCGAGCAGCCGTGCAACTGGGGTCCCGGCGCGTTTTAGCGGCTCTGGA  
TCCGGCACGGATTTTACCCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGACTTATTATTGCC  
AGCAGATGTCTAATTATCCTGATACCTTTGGCCAGGGTACGAAAGTTGAAATTAACGTACG

<SEQ ID NO:71;DNA> PRO-026 VL

GATATCGCACTGACCCAGCCAGCTTCAGTGAGCGGCTCACCAGGTCAGAGCATTACCATCTCGTGTA  
CGGGTACTAGCAGCGATGTGGGCGGCTATAACTATGTGAGCTGGTACCAGCAGCATCCCGGGAAGGC  
GCCGAACTGATGATTTATGATGTGAGCAACCGTCCCTCAGGCGTGAGCAACCGTTTTAGCGGATCC  
20 AAAAGCGGCAACACCGCGAGCCTGACCATTAGCGGCCTGCAAGCGGAAGACGAAGCGGATTATTATT  
GCCAGAGCTATGACAATAATTCTGATGTTGTGTTTGGCGGCGGCACGAAGTTAACCGTTCTTGGCCA  
G

<SEQ ID NO:72;DNA> PRO-029 VL

25 GATATCGTGCTGACCCAGAGCCCGGCGACCCTGAGCCTGTCTCCGGGCGAACGTGCGACCCTGAGCT  
GCAGAGCGAGCCAGAGCGTGAGCAGCAGCTATCTGGCGTGGTACCAGCAGAAACCAGGTCAAGCACC  
GCGTCTATTAATTTATGGCGCGAGCAGCCGTGCAACTGGGGTCCCGGCGCGTTTTAGCGGCTCTGGA  
TCCGGCACGGATTTTACCCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGACTTATTATTGCC  
AGCAGACTAATAATGCTCCTGTTACCTTTGGCCAGGGTACGAAAGTTGAAATTAACGTACG

<SEQ ID NO:73;DNA> PRO-054 VL

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATCTCGTGTA  
GCGGCGATGCGCTGGGCGATAAATACGCGAGCTGGTACCAGCAGAAACCCGGGCGAGCGCCAGTTCT  
GGTGATTTATGATGATTCTGACCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAACAGCGGC  
35 AACACCGCGACCCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATTGCCAGAGCT  
ATGACTATTTTAAGCTTGTGTTTGGCGGCGGCACGAAGTTAACCGTTCTTGGCCAG

<SEQ ID NO:74;DNA> PRO-055 VL

GATATCGCACTGACCCAGCCAGCTTCAGTGAGCGGCTCACCAGGTCAGAGCATTACCATCTCGTGTA  
40 CGGGTACTAGCAGCGATGTGGGCGGCTATAACTATGTGAGCTGGTACCAGCAGCATCCCGGGAAGGC  
GCCGAACTGATGATTTATGATGTGAGCAACCGTCCCTCAGGCGTGAGCAACCGTTTTAGCGGATCC  
AAAAGCGGCAACACCGCGAGCCTGACCATTAGCGGCCTGCAAGCGGAAGACGAAGCGGATTATTATT  
GCCAGAGCTATGACATGTATAATTATATTGTGTTTGGCGGCGGCACGAAGTTAACCGTTCTTGGCCA  
G

45 In yet another preferred embodiment the pharmaceutical composition comprises a single chain Fv molecule (scFv) set forth in SEQ ID NO:37, having corresponding polynucleotide sequence SEQ ID NO:38, and a pharmaceutically acceptable carrier. The respective polypeptide and polynucleotide sequences are presented herein:

**PRO-001 scFv polypeptide (SEQ ID NO:37)**

MLTCAISGNS VSSNSAAWNW IRQSPGRGLE WLGRTYYRSK WYNDYAVSVK  
 SRITINPDTS KNQFSLQLNS VTPEDTAVYY CARSYYPDFD YWGQGLTVTV SSAGGSGGGG  
 GSGGGSGGG GSDIELTQPP SVSVAPGQTA RISCSDALG  
 5 DKYASWYQQK PGQAPVLVIY DDSRPSGIP ERFSGSNSGN TATLTISGTQ  
 AEDEADYYCQ SYDGPDLWVF GGGTKLTVLG QEFDYKMTMT KRAVEPPAV

**PRO-001 scFv DNA (SEQ ID NO:38)**

1 ATGCTGACCT GTGCGATTTC CGGGAATAGC GTGAGCAGCA ACAGCGCGGC  
 10 GTGGAAGTGG ATTCGCCAGT CTCCTGGGCG TGGCCTCGAG TGGCTGGGCC GTACCTATTA  
 TCGTAGCAAA TGGTATAACG ATTATGCGGT GAGCGTGAAA AGCCGGATTA CCATCAACCC  
 GGATACTTCG AAAAACCAGT TTAGCCTGCA ACTGAACAGC GTGACCCCGG AAGATACGGC  
 CGTGTATTAT TGC GCGCGT CTTATTATCC TGATTTTGAT TATTGGGGCC AAGGCACCCT  
 GGTGACGGTT AGCTCAGCGG GTGGCGGTTT TGGCGGCGGT GGGAGCGGTG GCGGTGGTTC  
 15 TGGCGGTGGT GGTTCGATA TCGAACTGAC CCAGCCGCTT TCAGTGAGCG TTGCACCAGG  
 TCAGACCGCG CGTATCTCGT GTAGCGGCGA TGC GCTGGGC GATAAATACG CGAGCTGGTA  
 CCAGCAGAAA CCCGGGCAGG CGCCAGTTCT GGTGATTTAT GATGATTCTG ACCGTCCCTC  
 AGGCATCCCG GAACGCTTTA GCGGATCCAA CAGCGGCAAC ACCGCGACCC TGACCATTAG  
 CGGCACTCAG GCGGAAGACG AAGCGGATTA TTATTGCCAG AGCTATGACG GTCCTGATCT  
 20 TTGGGTGTTT GCGGCGGCA CGAAGTTAAC CGTCTTGGC CAGGAATTCG ACTATAAGAT  
 GACGATGACA AAGCGCGCCG TGGAGCCACC CGCAGTTTGA

Table 3: V<sub>H</sub>-CDR3 and corresponding V<sub>L</sub>-CDR3 polynucleotide sequence

Clone	V <sub>H</sub> -CDR3	V <sub>L</sub> -CDR3
PRO-001	TCTTATTATC CTGATTTTGA TTAT (SEQ ID NO:39)	CAGAGCTATG ACGGTCCTGA TCTTTGG (SEQ ID NO:48)
PRO-002	GATTTTCTTG GTTATGAGTT TGATTAT (SEQ ID NO:40)	CAGAGCTATG ACTATTCTGC TGATTAT (SEQ ID NO:49)
PRO-012	TATCATTCTT GGTATGAGAT GGGTT ATTAT GGTCTACTG TTGGTTATAT GTTTGATTAT (SEQ ID NO:41)	CAGAGCTATG ACTTTGATTT TGCT (SEQ ID NO:50)
PRO-021	GATAATTGGT TTAAGCCTTT TTCTGATGTT (SEQ ID NO:42)	CAGCAGTATG ATTCTATTCC TTAT (SEQ ID NO:51)
PRO-024	GTAAATCATT GGACTTATAC TTTTGATTAT (SEQ ID NO:43)	CAGCAGATGT CTAATTATCC TGAT (SEQ ID NO:52)
PRO-026	GGTTATTGGT ATGCTTATTT TACTTATATT AATTATGGTT ATTTTGATAAT (SEQ ID NO:44)	CAGAGCTATG ACAATAATTC TGATGTT (SEQ ID NO:53)
PRO-029	ACTTGGCAGT ATTCTTATTT TTATTATCTT GATGGTGGTT ATTATTTTGA TATT (SEQ ID NO:45)	CAGCAGACTA ATAATGCTCC TGTT (SEQ ID NO:54)
PRO-054	AATATGGCTT ATACTAATTA TCAGTATGTT AATATGCCTC ATTTTGATTA T (SEQ ID NO:46)	CAGAGCTATG ACTATTTTAA GCTT (SEQ ID NO:55)
PRO-055	TCTATGAATT CTACTATGTAT TGGTATCTTC GTCGTGTTCTT TTTGATCAT (SEQ ID NO:47)	CAGAGCTATG ACATGTATAA TTATATT (SEQ ID NO:56)

### Antibodies

Antibodies, or immunoglobulins, comprise two heavy chains linked together by disulfide bonds and two light chains, each light chain being linked to a respective heavy chain by disulfide bonds in a "Y" shaped configuration. Proteolytic digestion of an antibody yields Fv (Fragment variable and Fc (fragment crystalline) domains. The antigen binding domains, Fab, include regions where the polypeptide sequence varies. The term F(ab')<sub>2</sub> represents two Fab' arms linked together by disulfide bonds. The central axis of the antibody is termed the Fc fragment. Each heavy chain has at one end a variable domain (V<sub>H</sub>) followed by a number of constant domains (C<sub>H</sub>). Each light chain has a variable domain (V<sub>L</sub>) at one end and a constant domain (C<sub>L</sub>) at its other end, the light chain variable domain being aligned with the variable domain of the heavy chain and the light chain constant domain being aligned with the first constant domain of the heavy chain (CH1).

The variable domains of each pair of light and heavy chains form the antigen-binding site. The domains on the light and heavy chains have the same general structure and each domain comprises four framework regions, whose sequences are relatively conserved, joined by three hypervariable domains known as complementarity determining regions (CDR1-3). These domains contribute specificity and affinity of the antigen-binding site.

The isotype of the heavy chain (gamma, alpha, delta, epsilon or mu) determines immunoglobulin class (IgG, IgA, IgD, IgE or IgM, respectively). The light chain is either of two isotypes (kappa,  $\kappa$  or lambda,  $\lambda$ ) found in all antibody classes.

It should be understood that when the terms "antibody" or "antibodies" are used, this is intended to include intact antibodies, such as polyclonal antibodies or monoclonal antibodies (mAbs), as well as proteolytic fragments thereof such as the Fab or F(ab')<sub>2</sub> fragments. Further included within the scope of the invention are chimeric antibodies; human and humanized antibodies; recombinant and engineered antibodies, and fragments thereof. Furthermore, the DNA encoding the variable region of the antibody can be inserted into the DNA encoding other antibodies to produce chimeric antibodies (see, for example, US patent 4,816,567). Single chain antibodies fall within the scope of the present invention. Single chain antibodies can be single chain composite polypeptides having antigen binding capabilities and comprising amino acid sequences homologous or analogous to the variable regions of an immunoglobulin light and heavy chain (linked V<sub>H</sub>-V<sub>L</sub> or single chain Fv (ScFv)). Both V<sub>H</sub> and V<sub>L</sub> may copy natural monoclonal antibody sequences or one or both

of the chains may comprise a CDR-FR construct of the type described in US patent 5,091,513, the entire contents of which are incorporated herein by reference. The separate polypeptides analogous to the variable regions of the light and heavy chains are held together by a polypeptide linker. Methods of production of such single chain antibodies, particularly where the DNA encoding the polypeptide structures of the V<sub>H</sub> and V<sub>L</sub> chains are known, may be accomplished in accordance with the methods described, for example, in US patents 4,946,778, 5,091,513 and 5,096,815, the entire contents of each of which are incorporated herein by reference.

Additionally, CDR grafting may be performed to alter certain properties of the antibody molecule including affinity or specificity. A non-limiting example of CDR grafting is disclosed in US patent 5,225,539.

A "molecule having the antigen-binding portion of an antibody" as used herein is intended to include not only intact immunoglobulin molecules of any isotype and generated by any animal cell line or microorganism, but also the antigen-binding reactive fraction thereof, including, but not limited to, the Fab fragment, the Fab' fragment, the F(ab')<sub>2</sub> fragment, the variable portion of the heavy and/or light chains thereof, Fab miniantibodies (see WO 93/15210, US patent application 08/256,790, WO 96/13583, US patent application 08/817,788, WO 96/37621, US patent application 08/999,554, the entire contents of which are incorporated herein by reference), dimeric bispecific miniantibodies (see Muller, et al, 1998) and chimeric or single-chain antibodies incorporating such reactive fraction, as well as any other type of molecule or cell in which such antibody reactive fraction has been physically inserted, such as a chimeric T-cell receptor or a T-cell having such a receptor, or molecules developed to deliver therapeutic moieties by means of a portion of the molecule containing such a reactive fraction. Such molecules may be provided by any known technique, including, but not limited to, enzymatic cleavage, peptide synthesis or recombinant techniques.

The term "Fc" as used herein is meant as that portion of an immunoglobulin molecule (Fragment crystallizable) that mediates phagocytosis, triggers inflammation and targets Ig to particular tissues; the Fc portion is also important in complement activation.

In one embodiment of the invention, a chimera comprising a fusion of the extracellular domain of the RPTK and an immunoglobulin constant domain can be constructed useful for assaying for ligands for the receptor and for screening for antibodies and fragments thereof

The "extracellular domain" when used herein refers the polypeptide sequence of the FGFR3 disclosed herein which are normally positioned to the outside of the cell. The extracellular domain encompasses polypeptide sequences in which part of or all of the adjacent (C-terminal) hydrophobic transmembrane and intracellular sequences of the mature FGFR3 have been deleted. Thus, the extracellular domain-containing polypeptide can comprise the extracellular domain and a part of the transmembrane domain. Alternatively, in the preferred embodiment, the polypeptide comprises only the extracellular domain of the FGFR3. The truncated extracellular domain is generally soluble. The skilled practitioner can readily determine the extracellular and transmembrane domains of the FGFR3 by aligning it with known RPTK (receptor protein tyrosine kinases) amino acid sequences for which these domains have been delineated. Alternatively, the hydrophobic transmembrane domain can be readily delineated based on a hydrophobicity plot of the polypeptide sequence. The extracellular domain is N-terminal to the transmembrane domain.

15 The term "epitope" is meant to refer to that portion of any molecule capable of being bound by an antibody or a fragment thereof which can also be recognized by that antibody. Epitopes or antigenic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and have specific three-dimensional structural characteristics as well as specific charge characteristics.

20 An "antigen" is a molecule or a portion of a molecule capable of being bound by an antibody which is additionally capable of inducing an animal to produce antibody capable of binding to an epitope of that antigen. An antigen may have one or more than one epitope. The specific reaction referred to above is meant to indicate that the antigen will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.

A "neutralizing antibody" as used herein refers to a molecule having an antigen-binding site to a specific receptor capable of reducing or inhibiting (blocking) activity or signaling through a receptor, as determined by in vivo or in vitro assays, as per the specification.

30 A "monoclonal antibody" or "mAb" is a substantially homogeneous population of antibodies to a specific antigen. mAbs may be obtained by methods known to those skilled in the art. See, for example Kohler et al (1975); US patent 4,376,110; Ausubel et al (1987-

1999); Harlow et al (1988); and Colligan et al (1993), the contents of which references are incorporated entirely herein by reference. The mAbs of the present invention may be of any immunoglobulin class including IgG, IgM, IgE, IgA, and any subclass thereof. A hybridoma producing an mAb may be cultivated *in vitro* or *in vivo*. High titers of mAbs  
5 can be obtained *in vivo* production where cells from the individual hybridomas are injected intraperitoneally into pristine-primed Balb/c mice to produce ascites fluid containing high concentrations of the desired mAbs. MAb of isotype IgM or IgG may be purified from such ascites fluids, or from culture supernatants, using column chromatography methods well known to those of skill in the art.

10 Chimeric antibodies are molecules, the different portions of which are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. Antibodies which have variable region framework residues substantially from human antibody (termed an acceptor antibody) and complementarity determining regions substantially from a mouse antibody (termed a donor  
15 antibody) are also referred to as humanized antibodies. Chimeric antibodies are primarily used to reduce immunogenicity in application and to increase yields in production, for example, where murine mAbs have higher yields from hybridomas but higher immunogenicity in humans, such that human/murine chimeric mAbs are used. Chimeric antibodies and methods for their production are known in the art (Better et al, 1988; Cabilly  
20 et al, 1984; Harlow et al, 1988; Liu et al, 1987; Morrison et al, 1984; Boulianne et al, 1984; Neuberger et al, 1985; Sahagan et al, 1986; Sun et al, 1987; Cabilly et al; European Patent Applications 125023, 171496, 173494, 184187, 173494, PCT patent applications WO 86/01533, WO 97/02671, WO 90/07861, WO 92/22653 and US patents 5,693,762, 5,693,761, 5,585,089, 5,530,101 and 5,225,539). These references are hereby incorporated  
25 by reference.

Besides the conventional method of raising antibodies *in vivo*, antibodies can be generated *in vitro* using phage display technology. Such a production of recombinant antibodies is much faster compared to conventional antibody production and they can be generated against an enormous number of antigens. In contrast, in the conventional  
30 method, many antigens prove to be non-immunogenic or extremely toxic, and therefore cannot be used to generate antibodies in animals. Moreover, affinity maturation (i.e., increasing the affinity and specificity) of recombinant antibodies is very simple and

relatively fast. Finally, large numbers of different antibodies against a specific antigen can be generated in one selection procedure. To generate recombinant monoclonal antibodies one can use various methods all based on phage display libraries to generate a large pool of antibodies with different antigen recognition sites. Such a library can be made in several  
5 ways: One can generate a synthetic repertoire by cloning synthetic CDR3 regions in a pool of heavy chain germline genes and thus generating a large antibody repertoire, from which recombinant antibody fragments with various specificities can be selected. One can use the lymphocyte pool of humans as starting material for the construction of an antibody library. It is possible to construct naive repertoires of human IgM antibodies and thus create a  
10 human library of large diversity. This method has been widely used successfully to select a large number of antibodies against different antigens. Protocols for bacteriophage library construction and selection of recombinant antibodies are provided in the well-known reference text Current Protocols in Immunology, Colligan et al (Eds.), John Wiley & Sons, Inc. (1992-2000), Chapter 17, Section 17.1.

15 In another aspect, the present invention provides methods of preventing, attenuating or treating the symptoms of a T-cell mediated inflammatory or autoimmune disease comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a FGFR3 specific soluble receptor. A soluble receptor, also known as a secreted receptor, of the present invention comprises FGFR3 extracellular ligand binding  
20 sequences. The soluble receptor is able to freely circulate in the body and is useful for targeting, for example, a FGFR3 ligand. Without wishing to be bound by theory the soluble receptor binds the ligand, effectively inactivating it, since the FGFR3 ligand is then no longer able to bind with its biologic target in the body. An even more potent inhibitor consists of two soluble receptors fused together to a specific portion of an immunoglobulin  
25 molecule (Fc fragment). This produces a dimer, known as a fusion protein, composed of two soluble receptors which have a high affinity for the target, and a prolonged half-life. An example of this type of molecule is Enbrel® (etanercept) a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1, for the  
30 treatment of rheumatoid arthritis. The soluble receptor is produced by methods known in the art, including recombinant DNA technology and enzymatic techniques. In another aspect, the present invention provides a method of treating a T cell mediated inflammatory



or autoimmune disease by administering a composition comprising at least one therapeutically effective FGFR3 inhibitor wherein the inhibitor is a FGFR3 specific small organic molecule tyrosine kinase inhibitor, and a pharmaceutically acceptable carrier. According to certain embodiments of the present invention an organic tyrosine kinase inhibitor (TKI) having FGFR3 specificity is useful for preventing, attenuating or treating a T cell mediated inflammatory or autoimmune disease. Non-limiting examples of organic tyrosine kinase inhibitors include small molecule organic tyrosine kinase inhibitors such as SU10991, SU5402 and PD173074 (Paterson, et al. 2004; Grand, et al, 2004)

In yet another embodiment, the present invention provides a method of treating a T cell mediated inflammatory or autoimmune disease by administering a pharmaceutical composition comprising at least one FGFR3 inhibitor wherein the inhibitor is a FGFR3 specific peptide inhibitor, and a pharmaceutically acceptable carrier. A peptide inhibitor includes FGFR3 specific peptides, peptide analogs having amino acid sequence derived from the extracellular portion of the fibroblast growth factor receptor 3 (FGFR3) and peptidomimetics based on the structure of such peptides. The peptidomimetic of the invention may be similar in structure to AHNP, the small molecule form of an anti-HER2/neu peptidomimetic that has activity similar to the full monoclonal antibody Herceptin (Zhang et al., 2000).

In yet another embodiment, the present invention provides a method of treating a T cell mediated inflammatory or autoimmune disease by administering a pharmaceutical composition comprising at least one FGFR3 inhibitor wherein the inhibitor is a FGFR3 specific RNA inhibitor, and a pharmaceutically acceptable carrier. RNA inhibition (RNAi) is based on antisense modulation of FGFR3 in cells and tissues comprising contacting the cells and tissues with at least one antisense compound, including but not limited to double stranded RNA, (dsRNA), small interfering RNA (siRNA), ribozymes and locked nucleic acids (LNAs). Antisense (AS) technology and its enormous therapeutic potential has been reviewed extensively (Milhavet, 2003; Oplanska, 2002). In certain specific embodiments the RNA inhibiting molecule is an antisense oligonucleotide or an oligonucleotide mimetic comprising from about 8 to about 50 nucleotides. International patent application WO 03/023004 teaches antisense compounds, compositions and methods for modulating the expression of FGFR3. Methods of using these compounds for diseases associated with FGFR3, such as skeletal disorders and certain cancers, are disclosed therein.

In yet another embodiment, the present invention provides a method of treating a T cell mediated inflammatory or autoimmune disease by administering a pharmaceutical composition comprising at least one FGFR3 inhibitor wherein the inhibitor is a FGFR3 specific antagonist ligand, and a pharmaceutically acceptable carrier. For example, 5 copending application, PCT publication WO 03/094835, assigned to the assignee of the present invention, discloses FGF9 variant ligands having antagonistic activity toward FGFR3.

In yet another embodiment the present invention provides a method of treating a T cell mediated inflammatory or autoimmune disease by administering a pharmaceutical 10 composition comprising at least one FGFR3 inhibitor wherein the inhibitor is a FGFR3 specific inhibitor of heparan sulfate binding. In certain embodiments the heparan sulfate binding inhibitor is a natural or a synthetic compound including heparin and mimetics thereof.

In another embodiment, the present invention provides a method of treating a T cell 15 mediated inflammatory or autoimmune disease by administering a pharmaceutical composition comprising at least one FGFR3 inhibitor wherein the inhibitor is a DNA vaccine encoding FGFR3 or a fragment thereof, and a pharmaceutically acceptable carrier. DNA vaccination provides an effective means of long term antigen expression *in vivo* for the generation of both humoral and cellular immune responses. According to various 20 embodiments of the present invention the DNA vaccines encode active fragments of FGFR3, set forth in SEQ ID NO:75. The preferred polynucleotide fragments encode the extracellular domain polypeptide of FGFR3, in particular amino acids 1-370 or fragments thereof. The FGFR3 according to the present invention is preferably human, however other mammalian FGFR3 proteins are within the scope of the invention.

25 The amino acid sequence of FGFR3 IIIb isoform (NCBI access no: P22607) is denoted herein SEQ ID NO:75.

	MGAPACALAL	CVAVAIVAGA	SSESLGTEQR	VVGRAAEVPG	PEPGQQEQLV	FGSGDAVELS
	CPPPGGGPMG	PTVWVKDGTG	LVPSEVLVG	PQRLQVLNAS	HEDSGAYSCR	QRLTQRLCH
	FSVRVTDAPS	SGDDEGEDE	AEDTGVDTGA	PYWTRPERMD	KKLLAVPAAN	TVRFRCPAAG
30	NPTPSISWLK	NGREFRGEHR	IGGIKLRHQQ	WSLVMESVVP	SDRGNYTCVV	ENKFGSIRQT
	YTLDVLERSP	HRPILQAGLP	ANQTAVLGSD	VEFHCKVYSD	AQPHIQWLKH	VEVNGSKVGP
	DGTPYVTVLK	VSLESNASMS	SNTPLVRIAR	LSSGEGPTLA	NVSELELPAD	PKWELSRARL
	TLGKPLGEGC	FGQVMAEAI	GIDKDRAAKP	VTVAVKMLKD	DATDKDLSDL	VSEMEMMKMI
	GKHKNIINLL	GACTQGGPLY	VLVEYAAKGN	LREFLRARRP	PGLDYSFDTC	KPPEEQLTFFK
35	DLVSCAYQVA	RGMEYLASQK	CIHRDLAARN	VLVTEDNVMK	IADFGLARDV	HNLDYYKKT
	NGRLPVKWMA	PEALFDRVYT	HQSDVWSFGV	LLWEIFTLGG	SPYPGIPVEE	LFKLLKEGHR

MDKPANCTHD LYMIMRECWH AAPSORPTFK QLVEDLDRVL TVTSTDEYLD LSAPFEQYSP  
GGQDTPSSSS SGDDSVFAHD LLPPAPPSSG GSRT

5 The corresponding polynucleotide sequence (NCBI access no: AF245114) is denoted herein SEQ ID NO:76.

10 In another aspect the present invention provides a method of treating a T cell mediated inflammatory or autoimmune disease by administering a pharmaceutical composition comprising at least one FGFR3 inhibitor wherein the inhibitor is a FGFR3 specific heparin inhibitor or a heparin mimetic inhibitor. Heparin and other proteoglycans are known to be essential to growth factor binding to a receptor. In a non-limiting example, the present invention provides a heparin-like, polyanionic compound able to compete with heparin for binding to FGFR3.

#### Pharmacology

15 The present invention also contemplates pharmaceutical formulations, both for veterinary and for human medical use, which comprise as the active agent one or more of the FGFR3 inhibitors described in the invention, for the manufacture of a medicament for the treatment or prophylaxis of the conditions variously described herein.

20 In such pharmaceutical and medicament formulations, the active agent preferably is utilized together with one or more pharmaceutically acceptable carrier(s) therefore and optionally any other therapeutic ingredients. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof. The active agent is provided in an amount effective to achieve the desired pharmacological effect, as described above, and in a  
25 quantity appropriate to achieve the desired daily dose.

Typically, the molecules of the present invention comprising the antigen binding portion of an antibody or comprising another polypeptide including a peptidomimetic, antagonistic ligand or soluble receptor or an organic molecule or polynucleotide will be suspended in a sterile saline solution for therapeutic uses. The pharmaceutical  
30 compositions may alternatively be formulated to control release of active ingredient (molecule comprising the antigen binding portion of an antibody) or to prolong its presence in a patient's system. Numerous suitable drug delivery systems are known and include, e.g., implantable drug release systems, hydrogels, hydroxymethylcellulose, microcapsules,

liposomes, microemulsions, microspheres, and the like. Controlled release preparations can be prepared through the use of polymers to complex or adsorb the molecule according to the present invention. For example, biocompatible polymers include matrices of poly(ethylene-co-vinyl acetate) and matrices of a polyanhydride copolymer of a stearic acid dimer and sebacic acid (Sherwood et al, 1992). The rate of release of the molecule according to the present invention, i.e., of an antibody or antibody fragment, from such a matrix depends upon the molecular weight of the molecule, the amount of the molecule within the matrix, and the size of dispersed particles (Saltzman et al., 1989 and Sherwood et al., 1992). Other solid dosage forms are described in Ansel et al., 1990 and Gennaro, 1990.

10 The pharmaceutical composition of this invention may be administered by any suitable means, such as orally, topically, intranasally, subcutaneously, intramuscularly, intravenously, intra-arterially, intraarticular, intralesionally or parenterally. Ordinarily, intravenous (i.v.), intraarticular, topical or parenteral administration will be preferred.

It will be apparent to those of ordinary skill in the art that the therapeutically effective amount of the molecule according to the present invention will depend, *inter alia* upon the administration schedule, the unit dose of molecule administered, whether the molecule is administered in combination with other therapeutic agents, the immune status and health of the patient, the therapeutic activity of the molecule administered and the judgment of the treating physician. As used herein, a "therapeutically effective amount" refers to the amount of a molecule required to alleviate one or more symptoms associated with a disorder being treated over a period of time.

Although an appropriate dosage of a molecule of the invention varies depending on the administration route, type of molecule (polypeptide, polynucleotide, organic molecule etc.) age, body weight, sex, or conditions of the patient, and should be determined by the physician in the end, in the case of oral administration, the daily dosage can generally be between about 0.01mg to about 500 mg, preferably about 0.01mg to about 50 mg, more preferably about 0.1mg to about 10 mg, per kg body weight. In the case of parenteral administration, the daily dosage can generally be between about 0.001mg to about 100 mg, preferably about 0.001mg to about 10 mg, more preferably about 0.01mg to about 1 mg, per kg body weight. The daily dosage can be administered, for example in regimens typical of 1-4 individual administration daily. Other preferred methods of administration include intraarticular administration of about 0.01mg to about 100 mg per kg body weight. Various

considerations in arriving at an effective amount are described, e.g., in Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th ed., Pergamon Press, 1990; and Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, Pa., 1990.

The molecules of the present invention as active ingredients are dissolved, dispersed or  
5 admixed in an excipient that is pharmaceutically acceptable and compatible with the active ingredient as is well known. Suitable excipients are, for example, water, saline, phosphate buffered saline (PBS), dextrose, glycerol, ethanol, or the like and combinations thereof. Other suitable carriers are well known to those in the art. (See, for example, Ansel et al., 1990 and Gennaro, 1990). In addition, if desired, the composition can contain minor  
10 amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents.

The combined treatment of one or more of the molecules of the invention with an anti-inflammatory drug such as methotrexate or glucocorticoids may provide a more efficient treatment for inhibiting FGFR3 activity. In one embodiment, the pharmaceutical  
15 composition comprises the antibody, an anti-inflammatory drug and a pharmaceutically acceptable carrier.

#### Polynucleotides

The term "nucleic acid" and "polynucleotides" refers to molecules such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term  
20 should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides.

Within the scope of the present invention is a nucleic acid molecule encoding a FGFR3 inhibitor useful for the preparation of a medicament for the treatment for the conditions  
25 described herein. The nucleic acid molecule contains a nucleotide sequence having at least 75% sequence identity, preferably about 90%, and more preferably about 95% identity to the above encoding nucleotide sequence set forth in any one of SEQ ID NOS: 57-74, as would well understood by those of skill in the art. In the hypervariable regions of the heavy chain and light chain, the nucleic acid molecule contains a nucleotide sequence having at  
30 least 50% sequence identity, preferably about 70% and more preferably about 80% identity to the molecules set forth in any one of SEQ ID NOS: 39-56.

The invention also provides nucleic acids that hybridize under high stringency conditions to polynucleotides set forth in any one of SEQ ID NOs: 57-74 or the complement thereof. As used herein, highly stringent conditions are those which are tolerant of up to about 5%-25% sequence divergence, preferably about 5%-15%. Without  
5 limitation, examples of highly stringent (-10°C below the calculated  $T_m$  of the hybrid) conditions use a wash solution of 0.1 X SSC (standard saline citrate) and 0.5% SDS at the appropriate  $T_i$  below the calculated  $T_m$  of the hybrid. The ultimate stringency of the conditions is primarily due to the washing conditions, particularly if the hybridization conditions used are those which allow less stable hybrids to form along with stable hybrids.  
10 The wash conditions at higher stringency then remove the less stable hybrids. A common hybridization condition that can be used with the highly stringent to moderately stringent wash conditions described above is hybridization in a solution of 6 X SSC (or 6 X SSPE), 5 X Denhardt's reagent, 0.5% SDS, 100 µg/ml denatured, fragmented salmon sperm DNA at an appropriate incubation temperature  $T_i$ . See generally Sambrook *et al.*, Molecular  
15 Cloning: A Laboratory Manual, 2d edition, Cold Spring Harbor Press (1989)) for suitable high stringency conditions.

Stringency conditions are a function of the temperature used in the hybridization experiment and washes, the molarity of the monovalent cations in the hybridization solution and in the wash solution(s) and the percentage of formamide in the hybridization solution.  
20 In general, sensitivity by hybridization with a probe is affected by the amount and specific activity of the probe, the amount of the target nucleic acid, the detectability of the label, the rate of hybridization, and the duration of the hybridization. The hybridization rate is maximized at a  $T_i$  (incubation temperature) of 20-25°C below  $T_m$  for DNA:DNA hybrids and 10-15°C below  $T_m$  for DNA:RNA hybrids. It is also maximized by an ionic strength  
25 of about 1.5M  $\text{Na}^+$ . The rate is directly proportional to duplex length and inversely proportional to the degree of mismatching.

Specificity in hybridization, however, is a function of the difference in stability between the desired hybrid and "background" hybrids. Hybrid stability is a function of duplex length, base composition, ionic strength, mismatching, and destabilizing agents (if  
30 any).

The  $T_m$  of a perfect hybrid may be estimated for DNA:DNA hybrids using the equation of Meinkoth *et al* (1984), as

$$T_m = 81.5^{\circ}\text{C} + 16.6 (\log M) + 0.41 (\%GC) - 0.61 (\% \text{ form}) - 500/L$$

and for DNA:RNA hybrids, as

$$T_m = 79.8^{\circ}\text{C} + 18.5 (\log M) + 0.58 (\%GC) - 11.8 (\%GC)^2 - 0.56(\% \text{ form}) - 820/L$$

where M, molarity of monovalent cations, 0.01-0.4 M NaCl,

5           %GC, percentage of G and C nucleotides in DNA, 30%-75%,

          % form, percentage formamide in hybridization solution, and

          L, length hybrid in base pairs.

$T_m$  is reduced by 0.5-1.5°C (an average of 1°C can be used for ease of calculation) for each 1% mismatching. The  $T_m$  may also be determined experimentally. As increasing  
10 length of the hybrid (L) in the above equations increases the  $T_m$  and enhances stability, the full-length rat gene sequence can be used as the probe.

Filter hybridization is typically carried out at 68°C, and at high ionic strength (e.g., 5 - 6 X SSC), which is non-stringent, and followed by one or more washes of increasing stringency, the last one being of the ultimately desired high stringency. The equations for  
15  $T_m$  can be used to estimate the appropriate  $T_i$  for the final wash, or the  $T_m$  of the perfect duplex can be determined experimentally and  $T_i$  then adjusted accordingly.

The invention also provides for conservative amino acid variants of the molecules. Variants according to the invention also may be made that conserve the overall molecular structure of the encoded proteins. Given the properties of the individual amino acids  
20 comprising the disclosed protein products, some rational substitutions will be recognized by the skilled worker. Amino acid substitutions, *i.e.* "conservative substitutions," may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.

In another embodiment of the present invention the FGFR3 inhibitor is a RNA  
25 molecule, for example a RNA molecule disclosed in PCT publication WO 03/023004.

Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.

While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the inventions following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.

All references cited herein, including journal articles or abstracts, published or corresponding U.S. or foreign patent applications, issued U.S. or foreign patents, or any other references, are entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by references.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

## EXAMPLES

An important approach to inhibiting FGFR3 activity is the generation of reagents that block receptor signaling. Without wishing to be bound by theory, molecules which bind the extracellular domain of the receptor may inhibit the receptor by competing with FGF or heparin binding or, alternatively, by preventing receptor dimerization. Additionally, binding to the extracellular domain may accelerate receptor internalization and turnover. Molecules which block receptor activity intracellularly may do so by a number of mechanisms,



including, without limitation, blocking the ATP binding site or by preventing phosphorylation.

All the experiments were performed under the supervision and guidelines of the Animal Welfare Committee.

5 Example 1: Collagen Induced Arthritis (CIA)

Murine collagen-induced arthritis (CIA) is considered a useful model for studying human RA since the two diseases share numerous pathologic, immunological, and genetic features. The CIA model in mice results in a symmetric polyarthritis in which bone and cartilage erosion typically occur, 2-4 weeks after immunization with naive type II collagen  
10 on complete Freud's adjuvant (CFA).

Male DBA/1 mice ( 8-10 weeks old) were subject to an intradermal injection at the base of the tail with 200µg type II collagen purified from bovine articular cartilage emulsified in CFA. The mice received a booster injection of 200µg type II collagen emulsified in CFA three weeks after the first dose.

15 The mice were checked daily and each animal with edema in one or more limbs was randomly assigned to one of several groups for further treatment. The thickness of each affected hind paw was measured with microcalipers. The results are expressed as a direct measure of paw width in millimeters.

Example 2: Treatment of CIA mice with FGFR3 inhibitors

20 Each mouse was injected intraperitoneally on the day following disease onset (day 1) with 100 ug anti-FGFR3-ScFv or anti-FGFR3 Fab' or 20 mg/kg of a FGFR3 specific tyrosine kinase (TK) inhibitor (SU5402, Calbiochem, La Jolla, CA), followed by daily injections with 300µg anti-FGFR3 ScFv or anti-FGFR3 Fab' or with 20 mg/kg SU5402.

Figure 1 shows the results of the inflammatory response to the various FGFR3  
25 inhibitors. Day 0 refers to the day of boost. The untreated animals (●) show a steady increase in paw edema until day 5 where it begins to stabilize at approximately 3mm. All the treated animal responded to the anti-FGFR3 treatment. The anti-FGFR3 scFv treated animals (□) showed the greatest reduction in paw edema over a 13 day period, to approximately 1.9 mm. The anti-FGFR3 Fab treated animals (◆) showed a significant  
30 reduction as did the SU5402 (TK) inhibitor treated animals (▲).

### Example 3: Delayed Type Hypersensitivity (DTH) Assessments

The mouse model for cutaneous delayed type hypersensitivity reactions was used to investigate the effects of FGFR3 inhibitors on induced skin inflammation. Oxazolone solutions (2% and 0.5%) were prepared by dissolving 200 and 50 mg, respectively, of oxazolone in 8 ml of acetone and 2 ml of olive oil. Mice were challenged with oxazolone by topical application onto the abdomen of each mouse (100 $\mu$ l of 2% oxazolone) followed by 10 $\mu$ l of 0.5% oxazolone on the right ear after 6 days. Differences between right and left ear thickness, indicating DTH development, were measured after 24 hours using a microcaliper.

Figure 2 shows the results of the DTH assay. The CIA mice showed a strong inflammatory reaction to the collagen. The scFv and SU5402 (TK) treated mice exhibited no induction of edema. The anti-FGFR3 Fab treated mice exhibit a strong reaction which, without wishing to be bound to a certain theory, may indicate an immune reaction to the Fab itself. The antibody is a fully human protein that may elicit a reaction in this particular assay. These studies show that systemic administration of an anti-FGFR3 ScFv or TK inhibitor do not induce skin inflammation in this model of experimentally-induced skin inflammation in mice.

### Example 4: Interferon- $\gamma$ (INF- $\gamma$ ) secretion assay

Interferon- $\gamma$  secretion was determined in an ELISA assay. Leukocytes were isolated from mice spleens. One million ( $10^6$ ) cells were incubated in medium containing serum for 24 hour, in a 24 well plate coated with anti-CD3 and anti-CD28 antibodies. Supernatant from each sample was collected and assayed for presence of INF- $\gamma$ . The INF- $\gamma$  assay was performed as follows: 96 wells plates were coated with a monoclonal anti-INF- $\gamma$  dissolved in boric buffer. Different volumes of supernatant were added to each well and incubated for 1 hour. INF- $\gamma$  was detected using anti-INF- $\gamma$  mAb-biotin followed with alkaline phosphatase conjugated Streptavidin. PNPP substrate was added and the color intensity measured in ELISA reader at Absorbance 405nm. The anti-FGFR3 Fab and scFv antibodies showed reduced IFN- $\gamma$  secretion.

### Example 5: DNA Vaccines

PCT patent publications WO 00/06203 and WO 01/57056 describe a method for inducing protective immunity against multiple sclerosis and rheumatoid arthritis, respectively, the method comprising intramuscularly administering to a subject a naked

DNA nucleic acid construct encoding a cytokine. In this experiment a naked DNA nucleic acid construct encoding FGFR3 extracellular domain or an active fragment thereof is administered in an animal model mimicking multiple sclerosis, as described in example 6 or in a experimental rat model of rheumatoid arthritis (Lider et al., 1987) or other animal model of T cell mediated autoimmune diseases. Rats are immunized subcutaneously in the base-tail with 0.1 ml of CFA supplemented with 10 mg/ml heat-killed Mycobacterium tuberculosis H37Ra in oil (Difco Laboratories Inc., Detroit, MI). Rats are monitored for clinical signs daily by an observer blind to the treatment protocol.

Example 6: Experimental Autoimmune Encephalomyelitis (EAE)

Experimental allergic encephalomyelitis (EAE) is an autoimmune neurological disease elicited by sensitization of the animals to myelin basic protein from the central nervous system. EAE is considered by many to represent a model of the human disease multiple sclerosis. The ability of compounds of the FGFR3 inhibitors to prevent or attenuate the clinical symptoms of this autoimmune disease is tested.

EAE is induced in Lewis rats in which the disease displays onset of symptoms around day 10 after induction and spontaneous recovery around 18 days after induction of the disease. Eight-week old female Lewis rats are used in this model. The animals (5 per cage) are maintained on a 12-hour light/12 hour dark regimen, with food and water *ad libitum*. EAE was induced in these animals by immunization with purified guinea pig myelin basic protein emulsified in complete Freund's adjuvant. Guinea pig myelin basic protein (MBP) is prepared from spinal cord homogenates defatted with chloroform/ethanol and the isolated protein was purified using ion exchange chromatography. Each animal receives 50 micrograms of the purified protein. A solution of MBP (0.5 mg/ml) is emulsified with an equal volume of Complete Freund's Adjuvant containing 4 mg/ml of mycobacterium tuberculosis, and each animal receives 100 microliters (50 ul in each hind foot pad). Animals are treated with a single injection of anti-FGFR3 antibody or vehicle control administered intravenously in a volume of 2 ml. The time of treatment is varied from day 10 to day 18, post induction of disease, with five animals per group.

The present invention is exemplified by certain animal disease models. These models are intended as a non-limitative example used for illustrative purposes of the principles of the present invention. Other animal models, such as those described in Gregersen et al (2004), are useful for demonstrating the principles described herein.

## REFERENCES

- Ansel et al, Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th Ed. (Lea & Febiger 1990)
- 5 Ausubel, et al (Eds), Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (New York) (1987-1999)
- Better et al, ", Science 240d(4855):1041-1043 (1988)
- Boulianne, et al, Nature 312(5995):643-646 (1984)
- Colligan, et al (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (New York) (1992-2000)
- 10 Gennaro (ed.), Remington's Pharmaceutical Sciences, 18<sup>th</sup> Ed. (Mack Publishing Co., 1990)
- Grand EK, et al., Leukemia 18(5):962-66 (2004)
- Gregerson, JW, et al., Tiss. Antigens 63:383-394 (2004)
- Harlow, et al, Antibodies: A Laboratory Manual, CSHL (Cold Spring Harbor, NY) (1988)
- 15 Kohler and Milstein, Nature, 256(5517):495-497 (1975)
- Liu et al, PNAS USA, 84(10):3439-3443 (1987)
- Manabe, N, et al., Rheumatology 38:714-20, (1999)
- Milhavet, O, et al., Pharmacol. Rev. 55(4):629-48 (2003)
- Morrison et al., PNAS USA 81(21):6851-6855 (1984)
- 20 Muller, et al, FEBS Letters, 432:45-49 (1998)
- Nepom, GT, Curr Opin Immun 14:812-815 (2002)
- Neuberger et al, Nature 314(6008):268-270 (1985)
- Opalinska JB and Gewirtz AM, Nat Rev Drug Discov. 1(7):503-14 (2002)
- Ornitz, Novartis Found Symp 232:63-76; discussion 76-80, 272-82 (2001)
- 25 Paleolog, EM, Arthritis Res., 4(suppl 3):S81-90 (2002)
- Paterson, JL, et al., Br. J. Haematol. 124(5):595-603 (2004)
- Saltzman et al, Biophys. J. 55:163 (1989)
- Sambrook, J, Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA.
- 30 Simon, JA, Rev Invest Clin 53:452-459, (2001)
- Sherwood, et al., Biotechnology, 10(11):1446-9 (1992)
- Walsh, DA and Haywood, L, Curr Opin Investig Drugs, 2:1054-63 (2001)
- Zhang, HT, et al., Drug News Perspect 13(6):325-9 (2000)